戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 g suramin, a century-old, negatively charged antiparasitic drug.
2 us leishmaniasis disease in combination with antiparasitic drugs.
3 able Giardia-specific diagnostic testing and antiparasitic drugs.
4 e used for the development of more effective antiparasitic drugs.
5  is an overall unmet and urgent need for new antiparasitic drugs.
6 s gradual during malaria and is modulated by antiparasitic drugs.
7 e therefore emerged as promising targets for antiparasitic drugs.
8 eases and the potential of vinyl sulfones as antiparasitic drugs.
9  facilitate the eventual design of selective antiparasitic drugs.
10 ent opportunity for directed design of novel antiparasitic drugs.
11 sistant crops, as well as new antibiotic and antiparasitic drugs.
12  patients are treated with prednisone and/or antiparasitic drugs.
13 have not demonstrated a clinical benefit for antiparasitic drugs.
14 the prospects for using enzyme inhibitors as antiparasitic drugs.
15 ery and development of urgently needed novel antiparasitic drugs.
16                  At least 564 women received antiparasitic drugs according to a standard protocol.
17                                         Mass antiparasitic drug administration programs and other con
18 ents should be treated with corticosteroids, antiparasitic drugs, and shunting if hydrocephalus is pr
19                              Niclosamide, an antiparasitic drug approved for human use, has been rece
20                                 The only two antiparasitic drugs approved for its treatment, benznida
21 le for why ivermectin, an effective and safe antiparasitic drug at low nanomolar concentrations, beco
22       In this study, we show that the common antiparasitic drug atovaquone inhibits arbovirus replica
23 loroquine, tetracycline and a broad spectrum antiparasitic drug atovaquone.
24 itrichomonas foetus is a rational target for antiparasitic drug design because it is the primary enzy
25 ine proteases are exciting novel targets for antiparasitic drug design.
26 n Toxoplasma gondii is a rational target for antiparasitic drug design.
27 fication and validation of novel targets for antiparasitic drug discovery in veterinary medicine.
28 ng highlights exciting new opportunities for antiparasitic drug discovery resulting from major advanc
29     The approach is especially applicable to antiparasitic drug discovery where the phylogenetic dist
30 ghts the potential of covalent inhibition in antiparasitic drug discovery.
31 ia has been exploited for the development of antiparasitic drugs, especially those used to treat mala
32 ioselective approach to the synthesis of the antiparasitic drug fluralaner (Bravecto, presently sold
33 nt study demonstrated that combining these 2 antiparasitic drugs improves antiparasitic efficacy.
34 iscovery, facilitating the evaluation of new antiparasitic drugs in vitro and in animals, elucidating
35 bananas, and helminth infections by applying antiparasitic drugs, in two groups of wild black capuchi
36 rmectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19.
37                                          The antiparasitic drug ivermectin efficiently inhibits the r
38                                          The antiparasitic drug ivermectin was proposed as a repurpos
39 ubunits confers high-level resistance to the antiparasitic drug ivermectin.
40 r the past 30 years, only few broad-spectrum antiparasitic drugs (mainly topical permethrin and oral
41                                 Some HIV and antiparasitic drugs might induce diabetes, whereas helmi
42 ction for T. gondii mutants resistant to the antiparasitic drug monensin, we have isolated a strain t
43 iously, we found that the small molecule and antiparasitic drug nitazoxanide (NTZ) inhibits CU pathwa
44 preventive and therapeutic potentials of the antiparasitic drug Praziquantel as a possible antifibrot
45              We previously reported that the antiparasitic drug pyrimethamine (PYR) inhibits NRF2 in
46    In 21 studies, efficacy of treatment with antiparasitic drugs ranged from 0 to 100% (35.7% of 269
47 tion of its biosynthesis may provide a novel antiparasitic drug target.
48 eukaryotes, is a potential antimicrobial and antiparasitic drug target.
49 Ivermectin is an FDA-approved broad-spectrum antiparasitic drug that also exhibits antiviral properti
50 ministration of ivermectin, a broad-spectrum antiparasitic drug that also kills mosquitoes feeding on
51            Diminazene aceturate (DIZE) is an antiparasitic drug that has been reported to exert prote
52                             Atovaquone is an antiparasitic drug that selectively inhibits electron tr
53                       IVM is an FDA-approved antiparasitic drug that was discovered in the 1970s and
54 gram aimed at discovering novel DNA-targeted antiparasitic drugs, the phenylfuran-benzimidazole unfus
55 rinary medicine is exploiting the ability of antiparasitic drugs to make vertebrate blood toxic for b
56 bally, this is pushing discovery research of antiparasitic drugs toward new agents endowed with new m
57 cult to implement, lagging behind the use of antiparasitic drugs, vaccine development and transmissio
58         Albendazole is a new, broad-spectrum antiparasitic drug, which was approved recently by the F
59  followed by or concurrent with an effective antiparasitic drug, without ineffective antibiotics.